NCT06109779 2026-03-04
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
29 trialsNCT06282575 2026-02-24
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3 Recruiting
NCT05876754 2026-02-19
ProvIDHe
Servier
Phase 3 Recruiting
NCT07265674 2026-01-23
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3 Recruiting
NCT07328919 2026-01-09
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
TransThera Sciences (Nanjing), Inc.
Phase 3 Not yet recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT07155525 2025-09-18
NBCA-MS
Minia University
Phase 3 Recruiting
NCT03656536 2025-08-24
FIGHT-302
Incyte Corporation
Phase 3 Terminated
NCT06622057 2025-04-30
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
Phase 3 Not yet recruiting
NCT04003636 2025-04-23
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT04924062 2025-04-17
MK-3475-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02170090 2025-03-30
ACTICCA-1
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Active not recruiting
NCT02989857 2024-08-20
ClarIDHy
Servier
Phase 3 Completed
NCT03773302 2024-05-08
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
QED Therapeutics, a BridgeBio company
Phase 3 Terminated
NCT04961970 2021-07-14
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
Sun Yat-sen University
Phase 3 Unknown
NCT01926236 2020-01-28
ABC06
The Christie NHS Foundation Trust
Phase 3 Completed
NCT03771846 2019-12-05
HAIC Versus Systemic Chemotherapy for Unresectable ICC
Sun Yat-sen University
Phase 3 Unknown
NCT02082522 2019-08-28
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Concordia Laboratories Inc.
Phase 3 Terminated
NCT02200042 2019-08-28
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
NRG Oncology
Phase 3 Terminated
NCT01470443 2019-05-21
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Samsung Medical Center
Phase 3 Unknown
NCT02232490 2019-02-26
Hepko-V5
Immunitor LLC
Phase 3 Unknown
NCT03779035 2018-12-19
AdBTC-1
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03345303 2017-11-17
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 3 Unknown
NCT02798510 2016-06-22
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
Fudan University
Phase 3 Unknown
NCT02548195 2015-09-14
Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
Shanghai Zhongshan Hospital
Phase 3 Unknown
NCT00907413 2015-06-03
PDT
Weill Medical College of Cornell University
Phase 3 Terminated
NCT00869635 2014-02-06
S-1 and Photodynamic Therapy in Cholangiocarcinoma
Asan Medical Center
Phase 3 Completed
NCT00653978 2011-06-22
Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures
Changhai Hospital
Phase 3 Unknown